Friday, August 22, 2025

Bright Minds Bioscience Approved For Nasdaq Listing

There’s another Canadian firm set to trade on the Nasdaq market. Bright Minds Bioscience (CSE: DRUG) this morning announced that it has been approved to begin trading on the major big board exchange.

The company will see its equity begin trading on the major US exchange as of November 8, where it will trade under the symbol “DRUG”, similar to its listing here in Canada. The firm will remain dual listed, with the move to not affect its listing on the Canadian Securities Exchange.

“Our listing on Nasdaq marks an important corporate milestone for Bright Minds, as we continue to advance our innovative drug candidates in pursuit of an improved generation of targeted serotonin-based therapies,” commented Ian McDonald, CEO of Bright Minds.

In making the announcement, McDonald identified that the move was made as it works to provide further liquidity for its shareholders, with the Nasdaq being the most liquid exchange globally.

Bright Minds is currently focused on developing novel psychedelic-based drugs for the targeted treatment of pain, epilepsy, and neuropsychiatric disorders. The firm is pushing towards in-human trials for BMB-101, it’s lead drug candidate, which focuses on the treatment of Dravet syndrome. Trials are expected to begin in the first half of 2022.

Bright Minds Bioscience last traded at $9.00 on the CSE.


FULL DISCLOSURE: Bright Minds Biosciences is a client of Canacom Group, the parent company of The Deep Dive. The company has been compensated to cover Bright Minds Biosciences on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

One Response

Video Articles

A Medical Breakthrough the Market Overlooked | David Elsley – Cardiol Therapeutics

Why Grade Beats Size in Silver Mining | Frank Basa – Nord Precious Metals

Are Investors Missing the Start of the Next Commodity Supercycle? | Morgan Lekstrom – NexMetals

Recommended

Emerita Resources Expands El Cura Drill Program By 10,000 Metres As Deposit Remains Open For Expansion

ESGold Signs MOU For Tailings Project In Colombia With Grades Up To 42 g/t Gold, 280 g/t Silver

Related News

Bright Minds: Focusing On Second Generation Psychedelic Compounds – The Daily Dive

Starting off this week on the Daily Dive is that of Dr Gideon Shapiro, whom...

Monday, June 21, 2021, 01:30:00 PM

Bright Minds Applies For Nasdaq Listing

Bright Minds Biosciences (CSE: DRUG) has an eye for the US big boards. The company...

Wednesday, June 16, 2021, 07:33:59 AM

Bright Minds Moves Into Clinical Development Stage Following Positive Toxicity Results

Drug development continues for the Bright Minds Biosciences (CSE: DRUG) lead product. The firm this...

Monday, March 14, 2022, 07:54:42 AM

Bright Minds: Eight Capital Assigns $11.50 Price Target To Firm

Last week, Eight Capital launched coverage on a basket of psychedelic companies. This comes after...

Monday, September 20, 2021, 10:09:00 AM

Explainer: Anti Alzheimer’s, Dravet Syndrome, Epilepsy & Addiction Drugs – The Daily Dive

On today’s Daily Dive, Cassandra welcomes back Ian McDonald, CEO of Bright Minds Biosciences (CSE:...

Friday, September 10, 2021, 01:30:00 PM